Targeting angiotensin II type I receptors to reduce the risk of stroke in patients with hypertension

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 2, 2006, Pages 231-237

  Papadopoulos, Dimitris P ^a   Papademetriou, Vasilios ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Angiotensin receptor blocker (ARB); Hypertension; Stroke

Indexed keywords

AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; INDAPAMIDE; LISINOPRIL; LOSARTAN; NICARDIPINE; NITRENDIPINE; PERINDOPRIL; RAMIPRIL; TELMISARTAN;

AGED; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BRAIN PROTECTION; CLINICAL TRIAL; COUGHING; DRUG MECHANISM; DRUG TARGETING; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HIGH RISK PATIENT; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; STROKE; SYSTOLIC HYPERTENSION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CEREBROVASCULAR ACCIDENT; DRUG DELIVERY SYSTEMS; HUMANS; HYPERTENSION; RECEPTOR, ANGIOTENSIN, TYPE 1; RISK FACTORS;

EID: 33645802635     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.2.231     Document Type: Review

References (43)

1. MANCIA G: Prevention and treatment of stroke in patients with hypertension. Clin. Ther. (2004) 26:631-648.
2. CHRYSANT SG: Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence. J. Hum. Hypertens. 2005) 19:923-931
3. BECKETT NS: Prevention of stroke. Cardiovasc. Risk (2001) 8:257-264
4. LAW M, WALD N, MORRIS J: Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol. Assess. (2003) 7:1-94.
5. WEBER MA: Managing the patient at risk for a second stroke. J. Hypertens. (2005) 23(Suppl. 1):S41-S47.
6. FOURNIER A, MESSERLI FH, ACHARD JM, FERNADEZ L: Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J. Am. Coll. Cardiol. (2004) 43:1343-1347.
7. DAHLOF B, DEVEREUX RB, KJELDSEN SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet (2002) 359:995-1003.
8. LITHEEL I H, HANSOON L, SKOOG I et al.: The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens. (2003) 21:875-888.
9. SIERRA C, DE LA SIERRA A: Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Curr. Opin. Nephrol. Hypertens. (2005) 14:435-441.
10. GRASSI G, QUARTI F, MANCIA G Hypertension, antihypertensive treatment and stroke prevention. Neurol. Sci. (2005) 26(Suppl. 1):S22-S23.
11. MCFARLANE SI, SICA DA, SOWERS JR: Stroke in patients with diabetes and hypertension. J. Clin. Hypertens. (2005) 7:286-292.
12. CULMAN J, BLUME A, GOHLKE P, UNGER T: The renin-angiotensin system in the brain: possible therapeutic implications for AT (1)-receptor blockers. J. Hum. Hypertens. (2002) 16(Suppl. 3):S64-S70.
13. THONE-REINEKE C, ZIMMERMANN M, NEUMANN C et al.: Are angiotensin receptor blockers neuroprotective? Curr. Hypertens. Rep. (2004) 6:257-266
14. EPSTEIN BJ, GUMS JG: Can the renin-angiotensin system protect against stroke? A focus on angiotensin II receptor blockers. Pharmacotherapy (2005) 25:531-539
15. ITO T, YAMAKAWA H, BREGONIO C et al.: Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke (2002) 33:2297-2303
16. LU Q, ZHU YZ, WONG PT: Angiotensin receptor gene expression in candesartan mediated neuroprotection. Neuroreport (2004) 15:2643-2646
17. IWAI M, LIU HW, CHEN R et al.: Possible inhibition of focal cerebral ischemia by angiotensin II Type 2 receptor stimulation. Circulation (2004) 110:843-848.
18. ROSS A, PAPADEMETRIOU V: Candesartan cilexetil in cardiovascular disease. Expert Rev. Cardiovasc. Ther. (2004) 2:829-835.
19. NO AUTHORS LISTED: Tolerability and quality of life in ARB-treated patients. Am. J. Manag. Care (2005) 13(Suppl.):S392-S394.
20. FUCHS SA, KOOPMANS RP, GUCHELAAR HJ et al.: Are angiotensin II receptor antagonists safe in patients with previous angiotensin-converting enzyme inhibitor-induced angioedema? Hypertension (2001) 37:E1.
21. CHRYSANT SG: Stroke prevention with losartan in the context of other antihypertensive drugs. Drugs Today (2004) 40:791-801.
22. KJELDSEN SE, DAHLOF B, DEVEREUX RB et al.: LIFE (losartan intervention for endpoint reduction) study group effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a losartan intervention for endpoint reduction (LIFE) substudy. JAMA (2002) 288:1491-1498.
23. KJELDSEN SE, LYLE PA, KIZER JR et al.: LIFE Study Group. The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. J. Clin. Hypertens. (2005) 7:152-158.
24. TRENKWALDER P, ELMFELDT D, HOFMAN A et al.: The study on cognition and prognosis in the elderly (SCOPE) major CV events and stroke in subgroups of patients. Blood Press. (2005) 14:31-37.
25. PAPADEMETRIOU V, FARSANGC, ELMFELDT D et al.: Stroke prevention with the angiotensin II Type I-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the study on cognition and prognosis in the elderly (SCOPE). J. Am. Coll. Cardiol. (2004) 44:1175-1180.
26. SCHRADER J, ROTHENMEYER M, LUDERS S, KOLLMANN K: Hypertension and stroke: rationale behind the ACCESS trial. Basic Res. Cardiol. (1998) 93: 69-78.
27. SCHRADER J, LUDERS S, KULSCHEWSKI A et al.: The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke (2003) 34:1699-1703.
28. SCRADER J, LUDERS S, KULSCEWSKI A et al.: Morbidity and mortality After stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke (2005) 36:1218-1226.
29. DILAVERIS P, GIANNOPOULOS G, SYNETOS A, STEFANADIS C: The role of rennin angiotensin system blockade in the treatment of atrial fibrillation. Curr. Drug Targets Cardiovasc. Haematol. Disord. (2005) 5:387-403.
30. MORIWAKI H, UNO H, NAGAKANE Y et al.: Losartan, an angiotensin II (AT1) receptor antagonist, preserves cerebral blood flow in hypertensive patients with a history of stroke. J. Hum. Hypertens. (2004) 18:693-699.
31. OLSSON SB, HALPERIN JL: Prevention of stroke in patients with atrial fibrillation. Semin. Vasc. Med. (2005) 5:285-292.
32. HART RG Atrial fibrillation and stroke: four treatment controversies. Curr. Treat. Options Neurol. (2005) 7:491-498.
33. WACHTELL K, LENTO M, GERDTS E et al.: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for end point reduction in hypertension (LIFE) study. J. Am. Coll. Cardiol. (2005) 45:712-719.
34. WACHTELL K, HORNESTAM B, LEHTO et al.: Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The losartan intervention for end point reduction in hypertension (LIFE) study. J. Am. Coll. Cardiol. (2005) 45:705-711.
35. PROGRESS COLLABORATIVE GROUP: Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet (2001) 358:1033-1041.
36. HANSSON L, LINDHOLM LH, NISKANEN L et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP) randomised trial. Lancet (1999) 353:611-616.
37. ALLHAT OFFICERS AND COORDINATORS FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP: The antihypertensive and lipid-lowering treatment to prevent heart attack trial major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA (2002) 288:2981-2997.
38. SLEIGHT P: The ONTARGET/TRANSCEND trial programme: baseline data. Acta Diabetol. (2005) 42:550-556.
39. TEO K, YUSUF S, SLEIGHT P et al.: ONTARGET/TRANSCEND investigators rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease (ONTARGET/TRANSCEND) trials. Am. Heart J. (2004) 148:52-61.
40. WEBER MA: Creating a combination antihypertensive regimen: what does the research show? J. Clin. Hypertens. (2003) 5:12-20.
41. JAMERSON KA: The first hypertension trial comparing the effects of two fixed-dose combination therapy regimens on cardiovascular events: avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH). J. Clin. Hypertens. (2003) 5:29-35.
42. JAMERSON KA, BAKRIS GL, WUN CC et al.: Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am. J. Hypertens. (2004) 17:793-801.
43. WEDER AB: The avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: a comparison of first-line combination therapies. Expert Opin. Pharmacother. (2005) 6:275-281.